Skip to content
Open access

Pre-dementia clinical trajectories associated with neuronal α-synuclein neuropathologic change: a retrospective cohort study

Aug 2026 · Research Square · 0 citations · 11 references
Medicine

TL;DR

Heterogeneous pre-dementia trajectories are revealed and support is shown for combining α-synuclein detection with Alzheimer biomarkers, cognitive staging and multidomain clinical measures to improve prognosis and trial design are supported.

Abstract

Biological definitions of neuronal α-synuclein disease are advancing diagnosis beyond traditional clinical syndromes, but the trajectories preceding dementia and the influence of concomitant Alzheimer’s disease neuropathologic change (ADNC) remain uncertain. We analyzed longitudinal data from 1,543 participants without dementia at baseline who underwent repeated cognitive, functional, neuropsychiatric, and motor assessments and had neuropathological characterization at autopsy. Participants were classified as having neuronal α-synuclein neuropathologic change (NSNC), ADNC, or both. NSNC without intermediate or high ADNC was associated with the greatest motor burden. Among participants without mild cognitive impairment at baseline, concomitant ADNC was associated with earlier cognitive impairment and faster cognitive decline; mixed NSNC/ADNC also showed faster functional worsening than NSNC alone. Across participants with NSNC, baseline mild cognitive impairment, neuropsychiatric manifestations and concomitant ADNC predicted progression to dementia, whereas prespecified motor signs did not. These findings reveal heterogeneous pre-dementia trajectories and support combining α-synuclein detection with Alzheimer biomarkers, cognitive staging and multidomain clinical measures to improve prognosis and trial design.

Read PDF

Similar papers

Open access Sep 2026

Vascular and neurodegenerative contributions to cognitive decline and multidomain progression in de novo Parkinsons disease

INTRODUCTION: Cognitive decline in Parkinsons disease (PD) may reflect interacting neurodegenerative and cerebrovascular processes, but their distinct temporal contributions remain unclear. METHODS: Newly diagnosed, untreated PD participants from the PPMI who were cognitively normal at baseline and had at least three y...

R. Moqadam, H. Azizi, S. Raeesi et al. · 0 citations
Sep 2026

Comparison of baseline characteristics between cognitively normal and mild cognitive impairment and association of white matter hyperintensity trajectories with diagnostic outcomes, cognition, and amyloid-β protein: A longitudinal study

WMH baseline and trajectory changes are key risk factors for CN cognitive decline and WMH trajectory changes are linked to cognitive function and brain Aβ deposition.

W. Ba, Cui-Ping Bao, Ying-Xun Gong et al. · 0 citations
Open access Sep 2026

APOE4-dependent cholinergic/dopaminergic contributions to clinical symptoms across Alzheimer's disease spectrum: A retrospective observational study.

PURPOSE Clinical heterogeneity in Alzheimer's disease (AD) may reflect differential involvement of neurotransmitter systems, but whether the associations of cholinergic and dopaminergic imaging biomarkers with cognitive and neuropsychiatric symptoms differ according to apolipoprotein E ε4 (APOE4) status remains unclear...

Sung-Woo Kang, S. Jeon, Donggeon Lee et al. · 0 citations
Sep 2026

APOE4 moderates the association of sleep disturbance with cerebral amyloid burden but not with clinical conversion in cognitively normal older adults.

BackgroundSleep disturbance has been linked to Alzheimer's disease (AD), but whether its relationships with cerebral amyloid-β (Aβ) pathology and clinical progression are modified by APOE ε4 (APOE4) carrier status in cognitively normal elderly remains unclear.ObjectiveTo examine APOE4 moderation of the associations of...

Min-Ji Lee, Ji-Hyun Kim, H. Choi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.